SCHEMBL5007922

SCHEMBL5007922

Cn1c(C(=O)NCCCc2ccccc2)cc2c(O)cccc21

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.59
MAPT P10636 4/20 0.54
HPGD P15428 4/20 0.54
ALDH1A1 P00352 4/20 0.54
HSD17B10 Q99714 4/20 0.54
TSHR P16473 3/20 0.54
NPC1 O15118 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
HTT P42858 1/20 0.54
NLRP1 Q9C000 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.51
TP53 P04637 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
TDP1 Q9NUW8 1/20 0.50
KDM4E B2RXH2 5/20 0.49
LMNA P02545 2/20 0.49
MAPK1 P28482 1/20 0.49
ALOX15 P16050 1/20 0.49
POLB P06746 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4998210 0.97 L3MBTL1 (0.55) L3MBTL1MAPTHPGDALDH1A1HSD17B10
SCHEMBL5981594 0.93 MAPT (0.58) L3MBTL1MAPTHPGDALDH1A1HSD17B10
SCHEMBL2928038 0.82 KDM4E (0.47) L3MBTL1MAPTHPGDALDH1A1HSD17B10
SCHEMBL5008054 0.82 KDM4E (0.47) MAPTHPGDALDH1A1HSD17B10TSHR
SCHEMBL5002223 0.79 F10 (0.43) L3MBTL1MAPTHPGDALDH1A1HSD17B10
SCHEMBL5132653 0.76 MAPT (0.53) MAPTHPGDALDH1A1HSD17B10TSHR
SCHEMBL2929583 0.76 HSD17B10 (0.42) L3MBTL1MAPTHPGDALDH1A1HSD17B10
SCHEMBL5985923 0.76 KMT2A (0.62) L3MBTL1MEN1KMT2A
SCHEMBL4998178 0.75 RXFP1 (0.67) ALDH1A1NPSR1TP53RXFP1LMNA
SCHEMBL5005302 0.75 MLYCD (0.43) HPGDALDH1A1HSD17B10TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064143-B1 Positive modulators of nicotinic receptor agonists ASTRAZENECA AB (SE) 2006-06-20 US claimed
US-20050245595-A1 Positive modulators of nicotinic receptor agonists GURLEY DAVID 2005-11-03 US claimed
EP-1230218-A1 POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS AstraZeneca AB (SE) 2002-08-14 EP claimed
WO-2001032622-A1 POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS ASTRAZENECA AB (SE) 2001-05-10 WO claimed
US-7402604-B2 Positive modulators of nicotinic receptor agonists ASTRAZENECA AB (SE) 2008-07-22 US disclosed
US-7064143-B1 Positive modulators of nicotinic receptor agonists ASTRAZENECA AB (SE) 2006-06-20 US disclosed
US-20050245595-A1 Positive modulators of nicotinic receptor agonists GURLEY DAVID 2005-11-03 US disclosed
EP-1230218-A1 POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS AstraZeneca AB (SE) 2002-08-14 EP disclosed
WO-2001032622-A1 POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS ASTRAZENECA AB (SE) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245595-A1 Positive modulators of nicotinic receptor agonists CHRM1, CHRM2, CHRNA1 L3MBTL1 3369/4885MAPT 1941/4885HPGD 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.